Who is eligible for clinical trial NCT05281237?

Participants must meet protocol criteria for Stage I - II Primary Lung Cancer. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT05281237 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-04-07

Avecure Flexible Microwave Ablation Probe For Lung Nodules (NCT05281237)

🟢 Recruiting Observational / Diagnostic ⚙️ Medical Device Protocol Sponsor: Beth Israel Deaconess Medical Center

🩺 Plain-English Summary (8th-Grade Level)

This research study to determine the effectiveness of the AveCure Flexible Microwave Ablation Probe to destroy cancerous lung nodules up to 3 c m in size. This research study involves microwave ablation (MWA)

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (5 items) and avoid the listed exclusions (11 items).

Location: Beth Israel Deaconess Medical Center — Boston, Massachusetts

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Subject with Stage I - II primary lung cancer (Solitary nodules up to 3 cm) as defined by previous pathology or ROSE.
Pathological proof of target nodule/tumor type and malignancy with specimen considered adequate per institutional laboratory standards
Target nodule/tumor which can be accessed via navigational bronchoscopy and confirmed location with cone beam CT scan intra-operatively
Resection/surgical candidate (lobectomy or greater)
Participants must be at least 22 years old and able to provide consent

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Subjects in whom flexible bronchoscopy is contraindicated
Target nodule \< 1.0 cm
Prior radiation or neo adjuvant chemotherapy of the target nodule/tumor
Any comorbidity that the investigator feels would interfere with the safety of the subject or the evaluation of study objectives
Pacemaker, implantable cardioverter, or another electronic implantable device
Patient cannot tolerate bronchoscopy
Patients with coagulopathy
Patients in other therapeutic lung cancer studies
Subject is pregnant or breastfeeding
COVID-19 positive patient at the time of procedure.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

Beth Israel Deaconess Medical Center — Boston, Massachusetts

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

🏛️ View Official NIH Record ↗